Drugs / Grape Seed Extract
Grape Seed Extract
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03724578 | Jan 2019 → Feb 2020 | dental caries | Cairo University | Unknown | No outcome recorded |
| Phase 1 | NCT01820299 | Mar 2013 → May 2016 | — | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00713167 | Jul → Dec 2008 | hyperlipidemia | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00838266 | Feb → Mar 2009 | smooth surface dental caries | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05851183 | Jul 2023 → Sep 2024 | varicose disease | Yonsei University | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07236567 | Dec 2025 → Oct 2027 expected | dental pulp necrosis | Al-Azhar University | Not yet recruiting | No outcome recorded |
| — | NCT05927831 | May 2023 → Jan 2024 | dentin sensitivity | Manipal University College Malaysia | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT01185067 Comparator | Oct 2010 → Nov 2013 | diastolic heart failure, hypertensive disorder, hypertensive heart disease | University of Michigan | Completed | No outcome recorded |
| Phase 3 | NCT06440252 Comparator | Oct 2024 → Dec 2025 | — | RDC Clinical Pty Ltd | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Grape Seed Extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07236567 ↗ |
| Known as | Entelon | “Administer 150mg of Vitis Vinifera seed extract (Entelon®) orally twice a day” NCT05851183 ↗ |
| Known as | GSE | “either grape seed extract (GSE) or maltodextrin placebo capsules” NCT01185067 ↗1“OPC is the major part of Grape Seed Extract (GSE).” NCT01820299 ↗ |
| Known as | MegaNatural BP | “grape seed extract (MegaNatural BP, Polyphenolics, Inc.)” NCT01185067 ↗ |
| Known as | Vitis Vinifera seed extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05851183 ↗ |
| Route | Oral | “orally” NCT05851183 ↗ |